Gentamicin Sulfate Injection, Solution
Product Images NDC 51662-1597

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gentamicin Sulfate (NDC 51662-1597). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pouch (51662 1597 2 Pouch Label)

Pouch (51662 1597 2 Pouch Label)
Gentamicin Sulfate Injection is a medication that comes in a 2L vial and contains 80mg/2mL (48mg/nL). The product contains NET He x:ylylparaben and TSoke E. The medication should be stored at 20-25% capacity. The provided text also contains an identification code of Siee2 13972 and a prescription number of ORICINAL NFG O+ 8489-1207-83.*
FDA Label Image

Case (51662 1597 3 Case Label)

Case (51662 1597 3 Case Label)
Gentamicin Sulfate Injection is a medication that comes in vials of 2mL each and is sold in batches of 25. It has a strength of 80mg/2nL, which is equivalent to 40mg/mL. The medication is also referred to as Gentan Is Insase, and is dissolved in a solution containing sodium tartrate, hydroxide, and water. Its application may require supervision by a qualified physician or pharmacist.*
FDA Label Image

Serialized Rfid Label (51662 1597 3 Serialized Rfid Label)

FDA Label Image

Boxed Warning (Boxed)

Boxed Warning (Boxed)
This text provides warnings and precautions for the use of Gentamicin Sulfate Injection, USP, a type of aminoglycoside antibiotic. Patients receiving this medication should be closely monitored for potential toxicity, such as nephrotoxicity and neurotoxicity. Patients with impaired renal function and receiving high dosage or prolonged therapy are at a greater risk. Renal and eighth cranial nerve function should be monitored, and serum concentrations of aminoglycosides should be monitored to avoid potential toxic levels. Concurrent use of potentially neurotoxic or nephrotoxic drugs should be avoided. The use of gentamicin with potent diuretics should also be avoided as it may cause ototoxicity. Aminoglycosides can cause fetal harm when administered to pregnant women.*
FDA Label Image

Dosage 2 (Dosage 2)

FDA Label Image

Dosage 1 (Dosage)

Dosage 1 (Dosage)
This is a dosage schedule guide for adults with normal renal function. It provides dosages for various patient weights, ranging from 20 mg/mt to 225 mg/kg, to be administered at eight-hour intervals. The guide is specifically designed for the treatment of serious and life-threatening infections. The dosage amounts are provided as usual doses and doses for when the infection becomes severe. The table also indicates that the dosage of aminoglycoside should be recalculated periodically.*
FDA Label Image

Structure (Structure)

FDA Label Image

Vial Label (Vial Lable)

Vial Label (Vial Lable)
This is a description of a 2mL single-dose injection of Gentamicin Sulfate in USP, containing 80 mg/2 mL (40 mg/mL as Gentamicin) for L.V. or LM. use. It must be diluted for intravenous use. The NDC number is 0409-1207-13 and the product has Lot/Exp area (8VP).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.